In honor of World Thrombosis Day, the National Blood Clot Alliance („NBCA“), the nation’s leading patient advocacy organization dedicated to advancing the prevention, early diagnosis, and treatment of venous blood clots, is proud to announce its endorsement of DEFIANCE, a prospective, multinational, randomized controlled trial („RCT“) from Inari Medical that aims to advance clinical research for patients suffering from Deep Vein Thrombosis („DVT“). The DEFIANCE trial will evaluate and compare the clinical outcomes of certain symptomatic DVT patients following treatment with mechanical thrombectomy using Inari Medical’s ClotTriever System to treatment with anticoagulation medication alone.
The DEFIANCE trial will enroll up to 300 patients at up to 60 global sites. The trial’s primary endpoint will be a composite of: 1) treatment failure or therapy escalation rates, and 2) severity of PTS assessed at the 6-month follow-up. The study’s rigorous design will ensure that the results contribute to a better understanding of how these therapies perform in real-world practice, potentially guiding future treatment protocols and care decisions for DVT patients.
